Institutional shares held 221 Million
1.58M calls
1.36M puts
Total value of holdings $88B
$630M calls
$540M puts
Market Cap $104B
256,691,008 Shares Out.
Institutional ownership 86.28%
# of Institutions 1,724


Latest Institutional Activity in VRTX

Top Purchases

Q3 2024
Edgewood Management LLC Shares Held: 1.55M ($627M)
Q3 2024
Jennison Associates LLC Shares Held: 5.55M ($2.25B)
Q3 2024
Wellington Management Group LLP Shares Held: 4.8M ($1.94B)
Q3 2024
Capital Research Global Investors Shares Held: 9M ($3.65B)
Q3 2024
First Trust Advisors LP Shares Held: 575K ($233M)

Top Sells

Q3 2024
Mayflower Financial Advisors, LLC Shares Held: 1.48K ($601K)
Q3 2024
Goldman Sachs Group Inc Shares Held: 1.36M ($551M)
Q3 2024
Price T Rowe Associates Inc Shares Held: 1.77M ($717M)
Q3 2024
Geode Capital Management, LLC Shares Held: 5.94M ($2.41B)
Q3 2024
Amf Tjanstepension Ab Shares Held: 168K ($68.1M)

About VRTX

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 6 years of age or older who have at least one F508del mutation. Its pipeline includes VX-864 for the treatment of AAT deficiency, which is in Phase 2 clinical trial; VX-147 for the treatment of APOL1-mediated focal segmental glomerulosclerosis, or FSGS, and other serious kidney diseases which is in Phase 2 clinical trial; VX- 880, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-548, a NaV1.8 inhibitor for treatments of acute, neuropathic, musculoskeletal pain which is in Phase 2 clinical trial; and CTX001 for the treatment severe SCD and TDT which is in Phase 3 clinical trial. The company sells its products primarily to specialty pharmacy and specialty distributors in the United States, as well as specialty distributors and retail chains, and hospitals and clinics internationally. It has collaborations with Affinia Therapeutics, Inc.; Arbor Biotechnologies, Inc.; CRISPR Therapeutics AG.; Kymera Therapeutics, Inc.; Mammoth Biosciences, Inc.; Moderna, Inc.; Obsidian Therapeutics, Inc.; and Skyhawk Therapeutics, Inc.; as well as Ribometrix, Inc.; Genomics plc; Merck KGaA; Darmstadt, Germany, and X-Chem, Inc. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.


Insider Transactions at VRTX

Insider Transaction List

View all
Date Insider Transaction Ownership Type Shares Traded Value / Price
View All Transactions

Last 12 Months Summary

Buy / Acquisition
295K Shares
From 20 Insiders
Grant, award, or other acquisition 279K shares
Exercise of conversion of derivative security 15.9K shares
Sell / Disposition
345K Shares
From 27 Insiders
Sale (or disposition) back to the issuer 2.34K shares
Open market or private sale 197K shares
Payment of exercise price or tax liability 141K shares
Bona fide gift 4.6K shares

Track Institutional and Insider Activities on VRTX

Follow VERTEX PHARMACEUTICALS INC and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells VRTX shares.

Notify only if

Insider Trading

Get notified when an Vertex Pharmaceuticals Inc insider buys or sells VRTX shares.

Notify only if

News

Receive news related to VERTEX PHARMACEUTICALS INC

Track Activities on VRTX